Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline

Adcendo Denmark United States of America United Kingdom

Raises additional 16M EUR led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors.Funds will be used to further strengthen growing pipeline of first in class ADC assets, including lead asset targeting uPARAP.Iyona Rajkomar, Managing Partner at Dawn Biopharma, joins Adcendo Board of Directorsin April 2021, led by Novo Holdings and Ysios Capital, with participation from RA Capital Management, HealthCap and Gilde Healthcare. In April 2023, Adcendo announced a Series A extension of 31M EUR led by Pontifax Venture Capital and existing investors.

About Adcendo ApS

Adcendo ApS is developing breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers. In 2024, the company completed a Series A extension financing round, taking total funds raised to 98M EUR to advance, broaden, and accelerate the development of its first-in-class ADC pipeline assets. Investors include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, Gilde Healthcare and Dawn Biopharma, a platform controlled by KKR. For further information, please visit www.adcendo.com

About antibody-drug conjugates (ADCs)

ADCs are a class of highly potent biopharmaceutical drug composed of a targeting antibody linked to a biologically active drug or cytotoxic compound. ADCs combine the unique and very sensitive targeting capabilities of antibodies, with the potent effects of the conjugated cytotoxic drugs, allowing sensitive discrimination between healthy and cancer tissues. 

About Dawn BioPharma

Dawn Biopharma is a platform controlled by the KKR Healthcare Strategic Growth Fund II, established to own and support a diverse portfolio of companies committed to the development of highly innovative medicines and therapies.

 

View original content:https://www.prnewswire.co.uk/news-releases/adcendo-aps-announces-extension-of-series-a-financing-to-eur-98m-to-further-bolster-its-first-in-class-adc-pipeline-302156966.html